E-resources
PDF-
Larkin, James; Chiarion-Sileni, Vanna; Gonzalez, Rene; Grob, Jean-Jacques; Rutkowski, Piotr; Lao, Christopher D; Cowey, C. Lance; Schadendorf, Dirk; Wagstaff, John; Dummer, Reinhard; Ferrucci, Pier F; Smylie, Michael; Hogg, David; Hill, Andrew; Márquez-Rodas, Ivan; Haanen, John; Guidoboni, Massimo; Maio, Michele; Schöffski, Patrick; Carlino, Matteo S; Lebbé, Céleste; McArthur, Grant; Ascierto, Paolo A; Daniels, Gregory A; Long, Georgina V; Bastholt, Lars; Rizzo, Jasmine I; Balogh, Agnes; Moshyk, Andriy; Hodi, F. Stephen; Wolchok, Jedd D
New England journal of medicine/The New England journal of medicine, 10/2019, Volume: 381, Issue: 16Journal Article
With a 5-year minimum follow-up in patients with metastatic melanoma, overall survival at 5 years was 52% with a combination of nivolumab plus ipilimumab, as compared with 44% with nivolumab alone and 26% with ipilimumab alone. Programmed cell death ligand 1 expression did not influence the response rate or progression-free survival.
